Eloxx Pharmaceuticals Inc. (ELOX) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, ELOX scores 42 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 6 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and an FCF yield of -11.87%. For a prospective investor, this indicates the business is currently consuming cash relative to its capital base rather than generating it, so any valuation case depends on future cash generation that the source data does not demonstrate.
• Whale 13F Flow: 11 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is moderate-to-weak, indicating limited evidence of sustained institutional conviction in the source data.
• Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. It is the lowest-scoring pillar, meaning the insider-activity signal provides little support for the thesis.
• Macro Regime Fit: 12 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. The stock's market sensitivity is neutral at the index level, but the score reflects limited regime-based tailwinds.
• Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 1/9, and Debt/Equity is 0.5. The Piotroski reading is weak, while the Altman and leverage readings are less alarming, producing a mixed forensic picture.

Taken together, the investor implication is that the upside case rests on a turnaround in cash generation and institutional or insider conviction, both of which are currently weak in the source data. The valuation tradeoff is that a $53.3M market capitalization against negative ROIC and FCF yield leaves little demonstrated earnings support, so price moves are more likely to be driven by news flow and sentiment than by fundamentals. The 52-week range of $8.2 - $23.4 against the current $13.45 price illustrates this volatility.

Eloxx Pharmaceuticals Inc. (ELOX) is listed on NASDAQ in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the company profile, the market capitalization is $0.1B. Per the SEC financials, the company reported $0.0M revenue for FY 2025, so the source data does not establish a current product or customer base. Per the company profile, the business is classified as a biotechnology issuer; the source data does not describe specific products, customers, or revenue-generation mechanics.

Per the SEC financials, the company reported operating and net losses across all three listed periods, with gross, operating, and net margins shown as 0% in the market data. Per the market data, ROIC is -35% and the Roarable RQD rating cites a Piotroski F-Score of 1/9 and an Altman Z-Score of 2.5. Per the SEC financials, FY 2025 cash is $4.8M against $0.0M of reported debt, while FY 2024 cash is $0.1M; the source data does not report FY 2023 cash or debt.

• Director appointment (CATALYST, GREEN): Per the news wire, Eloxx announced the appointment of Geno Germano to its Board of Directors effective October 19, 2026. This is the only item flagged as a catalyst in the source data.
• Director option grant (MARKET WIRE, YELLOW): Per the news wire, Director Geno J. Germano received Eloxx options with a $12.50 exercise price.
• Analyst initiation (MARKET WIRE, YELLOW): Per the news wire, a Benzinga item describes an analyst beginning coverage on a bullish note; the source data does not identify the firm or rating.
• Market commentary (MARKET WIRE, YELLOW): Yahoo! Finance Canada, Stocktwits, and StockInvest.us items cover market action and forecasts without stating new fundamental events.
• Risk watch: The news wire contains no disclosed clinical, regulatory, or financing events in the source data.
• Butterfly Supply-Chain Graph: Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

• What specific products, programs, or clinical assets generate or are expected to generate revenue, given FY 2025 revenue of $0.0M?
• What is the source of the FY 2024 revenue of $6.4M, and does it recur?
• What are the company's cash runway and financing arrangements, given FY 2025 cash of $4.8M and negative FCF of $-6.3M?
• What is the identity and rating of the analyst initiation referenced in the news wire, and what are any price targets?
• What is the FY 2023 cash and debt position, which the source data reports as N/A?